Gastroenterology

Acino completes acquisition of M8 Pharmaceuticals significantly expanding presence and capabilities in Latin America

Retrieved on: 
Monday, December 4, 2023
Credit Suisse, Marketing, PWC, Caregiver, Acquisition, Stifel, Gastroenterology, CNS, Interim, Hematology, Patient, Creel, Cooley LLP, Fine chemical

This acquisition provides Acino with access to the two largest pharmaceutical markets in Latin America, significantly expanding its geographic footprint and strengthening its position in the region.

Key Points: 
  • This acquisition provides Acino with access to the two largest pharmaceutical markets in Latin America, significantly expanding its geographic footprint and strengthening its position in the region.
  • Integration of the M8 portfolio, pipeline, and operations with Acino is underway while both businesses continue to focus on their day-to-day operations.
  • Andrew Bird, Interim CEO at Acino commented: “I am delighted to complete this transformational deal for Acino.
  • I extend a warm welcome to nearly 300 new colleagues at M8 who have now joined the Acino family.”
    Joel Barlan, CEO at M8 commented: “Today marks an exciting new chapter for M8 and Acino.

When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…

Retrieved on: 
Thursday, November 30, 2023
Marketing, IBD, Failure, Adalimumab, Risankizumab, MOA, Gastroenterology, Physician, Ustekinumab, HCP, Ulcerative colitis, Injection, UC, RealTime, JAK, Patient, Celltrion, Upadacitinib, Pharmaceutical industry

Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.

Key Points: 
  • Over the past two months, the landscape of UC treatment has undergone a significant expansion, introducing four new options.
  • The first line of UC treatment remains overwhelmingly dominated by the firmly established anti-TNF therapies (such as Humira and Remicade) alongside Entyvio.
  • Furthermore, the favored choice among physicians in Crohn’s disease (CD), Stelara, has continued to enjoy a position in later-line UC treatment.
  • Patient Chart Dynamix™ is an independent, data-driven service unveiling real patient management patterns through rigorous analysis of large-scale patient chart audits.

American Board of Obesity Medicine announces more than 1,500 new diplomates as demand for better training and evidence-based obesity management grows

Retrieved on: 
Wednesday, December 20, 2023
Cardiology, Gastroenterology, Physician, Pessimism, Surgeon, Diabetes, Disease, Health, MD, Oncology, Certification, Cancer, Obesity, Stroke, American Medical Association, Attitude, Growth, Patient, Nursing

DENVER, Dec. 20, 2023 /PRNewswire-PRWeb/ --  American Board of Obesity Medicine announces more than 1,500 new diplomates as demand for better training and evidence-based obesity management grows Total number of board-certified doctors reaches 8,263

Key Points: 
  • Obesity has been officially recognized as a disease by the American Medical Association since 2013, and many doctors want to help patients lose weight and improve health.
  • Dr. Gudzune also noted that new anti-obesity medications can demand an enhanced level of sophistication and training.
  • ABOM Diplomates come from a wide spectrum of medical disciplines and specialties with primary care physicians comprising the largest number of Diplomates, said Dr. Korner.
  • The next obesity medicine certification exam will be administered October 14-26, 2024.

Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 13, 2023
Ministry, Food, MDR, Mortality, CE marking, Research, FDA, Hematochezia, R, Gastroenterology, Medical device, Retail, Health

“The past several months was an exciting period for the Company, as we executed against our strategy on several fronts.

Key Points: 
  • “The past several months was an exciting period for the Company, as we executed against our strategy on several fronts.
  • Financial Results for the Third Quarter Ended September 30, 2023
    The Company reported revenue of $86,000 for the third quarter 2023, compared to $278,000 for the same period last year.
  • Share data is on a split adjusted basis resulting from the Company’s reverse stock split effective as of November 2, 2023.
  • This balance included the fully funded credit facility with Kreos Capital, which has approximately $9.2 million due and outstanding as of September 30, 2023.

US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra

Retrieved on: 
Monday, November 13, 2023
HCP, Ustekinumab, Pfizer, Q3, JAK, Takeda, Patient, MOA, AbbVie, Colitis, Ulcerative colitis, Benchmarking, IBD, Launch, Upadacitinib, BMS, S1P, Infliximab, Adalimumab, Gastroenterology, Celltrion, UC, RealTime, Pharmaceutical industry, Tofacitinib, Vedolizumab, Lilly

These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.

Key Points: 
  • These additions come amidst an already bustling market, teeming with both branded and increasingly competitive biosimilar alternatives.
  • However, the influx of innovative agents suggests that upcoming changes are poised to be more substantial and transformative.
  • This extension enjoys the highest pre-launch familiarity and generates significantly higher interest in gaining approval.
  • Although prescribers display significant enthusiasm for Entyvio SC, its anticipated impact on the broader market is projected to be modest.

Intelligent Scopes Corp, Subsidiary of Claritas HealthTech, to Lead Global Delivery of CystoSmart™, an AI-Assisted Diagnostic Software for Bladder Cancer Detection in Endoscopic Images

Retrieved on: 
Monday, November 13, 2023
Bladder cancer, Health technology, Research, ISC, Times New Roman, Urology, FDA, Cystoscopy, Gastroenterology, Cancer, AI, Endoscopy, Khoo Teck Puat Hospital, NHG, Image, KTPH, Medical device

Claritas, a leader in image enhancement and AI diagnostic solutions has developed pioneering technology for real-time precision detection of conditions in endoscopic and cystoscopic images.

Key Points: 
  • Claritas, a leader in image enhancement and AI diagnostic solutions has developed pioneering technology for real-time precision detection of conditions in endoscopic and cystoscopic images.
  • Bladder cancer is the 10th most common cancer in the world, and the 6th most common in men.
  • Diagnostics using cystoscopes for examination of the bladder is challenging, and time and resource intensive.
  • Our aim has been to develop an AI diagnostic tool that enhances the accuracy of detection of bladder cancers.

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

Retrieved on: 
Friday, November 10, 2023
THR, Hepatology, MRE, AASLD, CAP, Hepatitis, Therapy, Incremental cost-effectiveness ratio, ELF, Fibrosis, Priority review, Treatment, Cirrhosis, Lipid, Division, Non-alcoholic fatty liver disease, Fatty liver disease, Atherosclerosis, Abstract, Diabetes, Histology, Biopsy, NDA, Electronic health record, ALT, Artificial intelligence, University, Marie Cassidy, NASH, Intelligence, Research, Disease, LDL, FDA, Radiation Exposure Compensation Act, Medical imaging, Pharmaceutical industry, Boston, Patient, Risk, Gastroenterology

Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.

Key Points: 
  • Resmetirom is a liver-directed thyroid hormone receptor (THR)-β agonist oral therapy that is designed to target key underlying causes of NASH.
  • It is the only investigational therapy for NASH that has achieved both fibrosis improvement and NASH resolution primary endpoints in a Phase 3 trial.
  • Resmetirom also reduced levels of LDL cholesterol and other lipids that are associated with heart disease.
  • Resmetirom is an investigational therapy and has not been approved by the FDA or any other regulatory authority.

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

Retrieved on: 
Friday, November 10, 2023
Hepatology, Safety, DNA, SAN, Therapy, PEI, HBsAg, AASLD, Emory University, Liver, Week, Doctor of Philosophy, B, CccDNA, Liver cancer, Hepatitis B virus, CHB, Entecavir, MBA, University, Hepatitis, Hong Kong, Physician, Poster, ETV, RNA, Vaccine, Pharmaceutical industry, HBeAg, Boston, New York University, Gastroenterology, Jacob Aligo

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that emerging hepatitis B antigen lowering data for its capsid assembly modulator – empty (CAM-E) drug, ALG-000184, are available as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), being held in Boston, Massachusetts, November 10 – 14, 2023.

Key Points: 
  • The data will be presented by Dr. Man-Fung Yuen, Chair and Professor of Gastroenterology and Hepatology at the University of Hong Kong, in Poster Hall C on Monday November 13 from 1-2 pm ET.
  • “ALG-000184 appears to have best-in-class antiviral properties which are also unique compared to other drug classes being evaluated for the treatment of chronic hepatitis B (CHB).
  • If the trends observed to date continue, ALG-000184 has the potential to become a cornerstone therapy in the treatment of CHB.
  • The antiviral effects of ALG-000184 presented at AASLD indicate that this drug is achieving significant viral suppression, likely via inhibition of cccDNA synthesis.

STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara

Retrieved on: 
Friday, November 10, 2023
Cytokine, European Economic Area, Safety, Dermatology, Perfusion, Psoriasis, EMA, Patient, Biosimilar, CHMP, Rheumatology, Psoriatic arthritis, Gastroenterology, Partnership, Adalimumab, Generic drug, Pharmaceutical industry, Vaccine, Ustekinumab

Under a strategic partnership begun in 2019, Alvotech is primarily responsible for developing and manufacturing the AVT04 ustekinumab biosimilar.

Key Points: 
  • Under a strategic partnership begun in 2019, Alvotech is primarily responsible for developing and manufacturing the AVT04 ustekinumab biosimilar.
  • STADA holds commercial rights within Europe, where the company already markets six approved biosimilars, including in gastrointestinal, dermatology and rheumatology indications.
  • STADA’s Global Specialty Head, Bryan Kim, commented: “This positive CHMP opinion puts STADA and Alvotech in prime position to improve patient access in the ustekinumab and interleukin inhibitor markets.
  • AVT04 was designed using the Sp2/0 host cell line and is manufactured using a perfusion process, like the reference product Stelara.

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Retrieved on: 
Thursday, November 9, 2023
Hepatology, Virology, Immune system, University of Hong Kong, AASLD, Patient, HBV, Clinical trial, Division, Non-cirrhotic portal fibrosis, Liver, University, Cancer, Autoimmunity, CFBV, Vaccine, Pharmaceutical industry, HBsAg, Gastroenterology

WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, and Barinthus Biotherapeutics plc (Nasdaq: BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, today announced a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023. The poster contains preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran (AB-729), with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy.

Key Points: 
  • The poster contains preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran (AB-729), with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy.
  • Preliminary immunology data suggests HBV-specific T cell IFN-γ production is enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
  • The preliminary safety data from this trial demonstrate that imdusiran and VTP-300 were both safe and well-tolerated.
  • Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma, commented, “Imdusiran consistently delivers compelling efficacy and safety data in multiple Phase 2a populations and combinations.